Cytotherapy, Journal Year: 2024, Volume and Issue: 26(5), P. 436 - 443
Published: Feb. 23, 2024
Language: Английский
Cellular and Molecular Immunology, Journal Year: 2024, Volume and Issue: 21(10), P. 1089 - 1108
Published: Aug. 12, 2024
Abstract In the past decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising immunotherapeutic approach for combating cancers, demonstrating remarkable efficacy in relapsed/refractory hematological malignancies both pediatric and adult patients. CAR-natural killer (CAR-NK) complements CAR-T by offering several distinct advantages. CAR-NK cells do not require HLA compatibility exhibit low safety concerns. Moreover, are conducive to “off-the-shelf” therapeutics, providing significant logistic advantages over cells. Both have shown consistent results malignancies. However, their against solid tumors remains limited due various obstacles including tumor trafficking infiltration, well an immuno-suppressive microenvironment. this review, we discuss recent advances current challenges of immunotherapies, with specific focus on application tumors. We also analyze depth drawbacks compared highlight CAR optimization. Finally, explore future perspectives these adoptive highlighting increasing contribution cutting-edge biotechnological tools shaping next generation cellular immunotherapy.
Language: Английский
Citations
31
Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)
Published: Jan. 13, 2025
The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, signaling molecules that interact promote growth therapeutic resistance. Elucidating the intricate interactions between cells TME crucial in understanding progression challenges. A critical process induced by epithelial-mesenchymal transition (EMT), wherein epithelial acquire mesenchymal traits, which enhance their motility invasiveness progression. By targeting various components TME, novel investigational strategies aim disrupt TME's contribution EMT, thereby improving efficacy, addressing resistance, offering a nuanced approach therapy. This review scrutinizes key players emphasizing avenues therapeutically components. Moreover, article discusses implications for resistance mechanisms highlights current toward modulation along with potential caveats.
Language: Английский
Citations
12
Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)
Published: Aug. 30, 2023
Recent advances in neoantigen research have accelerated the development of tumor immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody-based therapies, particularly for solid tumors. With next-generation sequencing bioinformatics technology, rapid identification prediction tumor-specific antigens (TSAs) has become possible. Compared with tumor-associated (TAAs), highly immunogenic TSAs provide new targets personalized immunotherapy can be used as prospective indicators predicting patient survival, prognosis, immune checkpoint blockade response. Here, characterization neoantigens clinical application neoantigen-based TCR-T strategies are summarized, current status, inherent challenges, translational potential these discussed.
Language: Английский
Citations
29
Cancers, Journal Year: 2025, Volume and Issue: 17(4), P. 589 - 589
Published: Feb. 9, 2025
Pancreatic cancer has the lowest 5-year survival rate (13%) among major cancers and is third leading cause of cancer-related deaths in United States. The high lethality this attributed to its insidious onset, late-stage diagnosis, rapid progression, limited treatment options. Addressing these challenges requires a deeper understanding complex tumor microenvironment identify novel therapeutic targets. Newer approaches like adoptive cell therapy have shown remarkable success treating hematological malignancies, but their application solid tumors, particularly pancreatic cancer, still early stages development. ACT broadly involves isolating immune cells (T lymphocytes, Natural Killer cells, macrophages) from patient, followed by genetic engineering enhance mount specific anti-tumor response. Various modalities are under investigation for including chimeric antigen receptor T (CAR-T), NK (CAR-NK), tumor-infiltrating lymphocytes (TIL), T-cell (TCR)-engineered cytokine-induced killer (CIK). Major hurdles been identifying actionable antigens delivering focused cellular therapies overcome immunosuppressive dense fibrotic stroma surrounding cancer. Further studies needed explore limitations faced combination order improve clinical outcomes.
Language: Английский
Citations
1
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: May 18, 2023
The treatment outcome of breast cancer is closely related to estrogen receptor (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) expression. Triple-negative (TNBC) lacking ER, PR, HER2 expression has limited options a poor prognosis. Tumor-infiltrating lymphocytes (TILs) play role in promoting or resisting tumors by affecting the tumor microenvironment are known as key regulators progression. However, treatments for TNBC (e.g., surgery, chemotherapy radiotherapy) have non-satisfaction’s curative effect so far. This article reviews different types TILs research progress adoptive cell therapy, aiming provide new therapeutic approaches TNBC.
Language: Английский
Citations
15
Gene Therapy, Journal Year: 2024, Volume and Issue: 31(7-8), P. 366 - 377
Published: March 14, 2024
Abstract Adoptive cell therapy (ACT), particularly chimeric antigen receptor (CAR)-T therapy, has emerged as a promising approach for targeting and treating rare oncological conditions. The orphan medicinal product designation by the European Union (EU) plays crucial role in promoting development of medicines conditions according to EU Orphan Regulation. This regulatory landscape analysis examines evolution, challenges, clinical outcomes genetically engineered ACT, with focus on CAR-T therapies, based Medicines Agency’s Committee Medicinal Products review applications evaluated maintenance status over 10-year period. In total, 30 36 were granted an status, 14 subsequently applied at time marketing authorisation or extension indication. Most products autologous therapies using lentiviral vector developed treatment haematological B-cell malignancies. findings revealed that 80% (29/36) submissions supported preliminary data showing potential efficacy candidate added benefit currently authorised proposed condition. Notably, 89% (32/36) cases significant new was accepted clinically relevant advantage existing therapies. Twelve fourteen reviewed indication demonstrated satisfactory methods within approved therapeutic indications, but one withdrawn during evaluation. article summarises key related use primarily cancers EU. It emphasises importance supporting medical plausibility stage highlights high success rate these obtaining initial designations subsequent maintaining
Language: Английский
Citations
5
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 8888 - 8888
Published: Aug. 15, 2024
RNA is a promising nucleic acid-based biomolecule for various treatments because of its high efficacy, low toxicity, and the tremendous availability targeting sequences. Nevertheless, shows instability has short half-life in physiological environments such as bloodstream presence RNAase. Therefore, developing reliable delivery strategies important disease sites maximizing therapeutic effect drugs, particularly field immunotherapy. In this mini-review, we highlight two major approaches: (1) vehicles (2) chemical modifications. Recent advances employ nanotechnologies lipid-based nanoparticles, viral vectors, inorganic nanocarriers to precisely target specific cell types facilitate cellular entry. On other hand, modification utilizes alteration structures via addition covalent bonds N-acetylgalactosamine or antibodies (antibody-oligonucleotide conjugates) receptors cells. The pros cons these technologies are enlisted review. We aim review acid their systems, strategies, related Finally, express our perspective on potential combination RNA-based click chemistry with adoptive therapy (e.g., B cells T cells) address issues duration associated antibody-oligonucleotide conjugate drugs.
Language: Английский
Citations
5
International Immunopharmacology, Journal Year: 2024, Volume and Issue: 144, P. 113392 - 113392
Published: Nov. 27, 2024
Language: Английский
Citations
4
Acta Biomaterialia, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
0
Journal of Gastroenterology and Hepatology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 8, 2025
Pancreatic and hepatobiliary cancers are increasing in prevalence contribute significantly to cancer-related mortality worldwide. Emerging therapeutic approaches, particularly immunotherapy, gaining attention for their potential harness the patient's immune system combat these tumors. Understanding role of cells tumor microenvironment (TME) metabolic reprogramming is key developing more effective treatment strategies. This review aims explore relationship between cell function glucose metabolism TME pancreatic cancers. synthesizes current research on adaptations cells, specifically focusing within We examine mechanisms by which influence progression through how interactions can be targeted purposes. Immune undergo significant changes, with playing a central modulating responses. These shifts not only affect but also behavior progression. The unique features provide new opportunities targeting responses malignancies effectively. complex offers promising By interventions, it may possible improve efficacy immunotherapies better aggressive
Language: Английский
Citations
0